Management of Postpartum Refractory Anemia with Elevated LDH and Thrombocytopenia

Diagnostic Approach

The American College of Obstetricians and Gynecologists recommends immediate evaluation for thrombotic microangiopathy (TMA), specifically atypical hemolytic uremic syndrome (aHUS) or HELLP syndrome, with urgent ADAMTS13 testing and consideration for complement blockade therapy if aHUS is confirmed 1
The triad of non-immune hemolytic anemia, thrombocytopenia, and elevated LDH in the postpartum period mandates urgent investigation for TMA 1
Essential laboratory tests include direct Coombs test, haptoglobin levels, peripheral blood smear, ADAMTS13 activity level, renal function, and coagulation studies 1, 2, 3

HELLP syndrome typically presents with hemolysis, elevated liver enzymes, and low platelets, usually resolving within days postpartum 2, 4
Atypical HUS should be suspected when thrombocytopenia and hemolysis persist or worsen beyond 72 hours postpartum, with renal involvement and ADAMTS13 activity >10% 1
TTP is characterized by ADAMTS13 activity <10% and may present with neurological symptoms 1

The British Journal of Anaesthesia recommends continuing supportive transfusion therapy as already initiated for HELLP syndrome, with maintenance of hemoglobin >7-8 g/dL with PRBCs, transfusion of platelets if count <50,000/mm³, and administration of FFP if PT/APTT prolonged or fibrinogen <2 g/L 2, 3, 5, 6, 7
For aHUS, initiate complement blockade with eculizumab immediately if thrombocytopenia is worsening beyond 72 hours postpartum, with rising creatinine or oliguria, and persistent hemolysis 1
For TTP, urgent plasma exchange is life-saving and should begin within hours of diagnosis, with avoidance of platelet transfusions unless life-threatening bleeding 1

ICU-level monitoring is recommended for the first 24-48 hours, with continuous vital signs, hourly urine output, and serial labs 2, 4
Hematology and nephrology consultation is recommended immediately if aHUS or TTP is suspected 1
HELLP syndrome typically resolves completely within 1 week postpartum with supportive care alone 2, 4
Atypical HUS has high mortality without complement blockade therapy, but excellent outcomes with eculizumab 1
TTP has >90% mortality untreated but >80% survival with prompt plasma exchange 1